# Study Comparing Cyclosporine Dose Reduction vs. Cyclosporine Elimination in Kidney Transplant Recipients Taking Sirolimus

> **NCT00195468** · PHASE4 · COMPLETED · sponsor: **Wyeth is now a wholly owned subsidiary of Pfizer** · enrollment: 280 (estimated)

## Conditions studied

- Kidney Failure
- Graft vs Host Disease

## Interventions

- **DRUG:** CYCLOSPORINE

## Key facts

- **NCT ID:** NCT00195468
- **Lead sponsor:** Wyeth is now a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-03
- **Primary completion:** 2006-11
- **Final completion:** 2006-11
- **Target enrollment:** 280 (ESTIMATED)
- **Last updated:** 2011-03-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00195468

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00195468, "Study Comparing Cyclosporine Dose Reduction vs. Cyclosporine Elimination in Kidney Transplant Recipients Taking Sirolimus". Retrieved via AI Analytics 2026-08-23 from https://api.ai-analytics.org/clinical/NCT00195468. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*